Lancet Market Research Report Information by Type (Safety Lancet, Push Button Safety Lancet, Pressure Activated Safety Lancet, Side Button Safety Lancet, and Personal Lancet), By End Users (Hospitals & Clinics, Diagnostic Centers and Pathology Laboratories, Home Diagnostics, and Research and Academic Laboratories), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

Lancet Market Overview

Lancet Market Size was valued at USD 1.95 Billion in 2023. The Global Lancet industry is projected to grow from USD 2.13 Billion in 2024 to USD 3.88 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.91% during the forecast period (2024 - 2032). Rising frequency of diabetes in senior citizens, children being capitulated to diabetes, and the increasing occurrences of contagious and non- contagious diseases are the key market drivers enhancing the market growth.

Lancet Market Trends

Growing Prevalence of diabetes to boost market growth

These have been a major concern that are attempted to be addressed by the medical community.  The root cause of the same can be traced back to unhealthy lifestyle which can result into increasing glucose level and give birth to diabetes. For instance, according to the International Diabetes Federation, presently, around 463 million people are living with diabetes and this figure is expected to rise 700 million by 2050.

Further, increasing diabetes in senior citizens and children, advanced technology, and home care systems also supports the market growth of the lancet. Government initiatives towards spreading diabetes awareness, heel-stick screening tests, severely burned patients, tests in infants are the other factors which drives the market growth in the coming years.

Additionally, according to the International Diabetes Federation’s Diabetes Atlas Tenth Edition, in the United States, 32.3 billion individuals had diabetes in 2021, and that number is expected to rise to 36.3 billion in the coming years. Similarly, 5,719,000 individuals were predicted to have diabetes in Canada, according to the Diabetes Canada 2022 report. In Canada, this number is anticipated to reach 7,277,000 by 2032.

Moreover, increase in contagious and non-contagious diseases such as swine flu, typhoid, cholera, heredity, ageing, and environmental factors rather than by harmful organisms is another factor driving the growth of the lancet market revenue.

Lancet Market Segment Insights

Lancet Type Insights

The market segments of Lancet, based on type, includes safety lancet, push button safety lancet, pressure activated safety lancet, side button safety lancet

, and personal lancet. The safety lancet segment held the majority share in 2022 in respect to the Lancet Market revenue. Safety lancet are single-use, sterile instruments used to take blood from capillaries. This is primarily owing to the affordability, easy availability, and no risk of sharp injuries, pre-setness, no requirement of needle loading or removal, and low exposure to infections across the globe. Safety Lancet are single-use,sterile instruments used to take blood from cappilaries.

The personal segment is the fastest growing sector in the coming years. The segment is expected to grow due to increase in diabetic patients, especially in aged population.

August 2017: 

HTL-STREFA S.A. contributed safety lancets to GLOBAL-MED, a Polish NGO. Ambulance from the Heart, was the name of the programmer that assisted in providing free glucose testing in moving cars during various healthcare events. The corporation aimed to increase its customer base in order to increase its market dominance internationally.

Lancet End User Insights

Based on End Users, the global lancet industry has been segmented into hospitals & clinics, diagnostic centers and pathology laboratories, home diagnostics, and research and academic laboratories. The hospitals & clinics segment held the largest share in 2022, owing to the rising incidents of infectious diseases and increasing number of diabetic patients that needs blood testing kits. Moreover, increasing government initiatives towards diabetes awareness and the cost of diagnostic in the hospitals and clinics more than homecare, is expected to bolster the market growth during the assessed timeline.

The homecare segment is the fastest growing segment in the lancet industry. The growth of the segment is due to availability of various lancet devices in the market and increasing awareness of self-monitoring of blood glucose level. Also, the cost of diagnostic blood glucose level at home is very low, and more diabetic patients prefer to diagnose with home care. Moreover, improvement in the patient self-care using lancet devices is driving the market growth in the near future.

December 2021:

According to Diabetes Care, careful discharge to scheduled outpatient management, a specialized inpatient diabetes programme using well-established standards, and preadmission treatment of hyperglycemia

in patients undergoing elective procedures all contribute to ease of hospital management of diabetes. The same source states that the required standard for the safe use of intravenous insulin for hospitalized patients is bedside blood glucose

testing every 30 minutes to every 2 hours. As a result, lancet are routinely used to take blood samples from hospitalized patients in order to check their blood glucose levels.

Lancet Regional Insights

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Lancet Market accounted for USD 0.54 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. This is attributed to the growing incidence of infectious diseases and diabetes, technology advancement with rising healthcare expenditure, as well as an ageing population across the region. As per The International Diabetes Federation, 43% of the total diabetes-related health expenses happens in the region.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 1: LANCET MARKET SHARE BY REGION 2022 (%)

 

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe lancet market accounts for the second-largest market share due to the availability of improved products, government backing for the growth of the healthcare industry, an ageing population, and an increase in incidence of diabetes. Further, the Germany market of lancet held the largest market share, and the UK market of lancet was the fastest growing market in the European region.

The Asia-Pacific lancet market is expected to grow at the fastest CAGR from 2022 to 2030. This is due to increasing demand for lancet and other similar products and advancement in healthcare infrastructure. Moreover, China market of lancet held the largest market share, and the India lancet market was the fastest growing market in the Asia-Pacific region.

For instance, India market of lancet is growing due to increasing infectious diseases such as, malaria, chikungunya, zika, and dengue.

Lancet Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of lancet grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the lancet industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global lancet industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, lancet industry has provided medicine with some of the most significant benefits. The lancet market major player such as HTL-STREFA S.A. (Poland), Terumo Corporation (Japan), Becton Dickinson and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Improve Medical Instruments Co.

Ltd. (US), Bayer AG (Germany), Sarstedt AG & Co. (Germany), Abbott Laboratories (US), Greiner Bio-One International GmbH (US), and others are working to expand the market demand by investing in research and development activities.

The mission of Abbott Laboratories, is to realize the promise of human potential in all contexts, facets, and epochs of life. Company thinks the secret to fulfilling that promise is good health and we can do anything when we are in good health. It will always strive to help people achieve their best health at every stage of their lives. This is how it live out that conviction every single day.

For Instance: The Freestyle Liber Flash, a glucose monitoring system from Abbott Laboratories that helps individuals monitor their glucose or sugar levels, was authorized by the US Food and Drug Administration. By providing cutting-edge items, the firm was able to build a superior portfolio.

Key Companies in the market of Lancet includes

• HTL-STREFA S.A. (Poland)
• Terumo Corporation (Japan)
• Becton Dickinson and Company (US)
• Hoffmann-La Roche Ltd. (Switzerland)
• Improve Medical Instruments Co. Ltd. (US)
• Bayer AG (Germany)
• Sarstedt AG & Co. (Germany)
• Abbott Laboratories (US)
• Greiner Bio-One International GmbH (US), among others

Lancet Industry Developments

• Q1 2025: Novo Holdings’ Purchase of Catalent Novo Holdings A/S completed its acquisition of leading CDMO Catalent for $16.5 billion. The deal includes three of Catalent’s fill-finish manufacturing sites and is intended to boost the production of Novo Nordisk’s diabetes and weight-loss drugs.
• Q2 2025: Lantheus acquisition of Evergreen Theragnostics Lantheus Holdings completed its acquisition of Evergreen Theragnostics for up to $1.0025 billion, including a $250 million upfront payment and up to $752.5 million in milestone payments, strengthening its radiopharmaceutical development and manufacturing capabilities.
• Q3 2024: Biogen acquired Human Immunology Biosciences Biogen acquired Human Immunology Biosciences in July 2024 as part of its strategy to expand its portfolio and reposition for growth in the pharmaceuticals and life sciences sector.
• Q3 2024: Eli Lilly acquired Morphic Eli Lilly completed the acquisition of Morphic in August 2024, aiming to strengthen its pipeline and focus on targeted therapeutic areas.
• Q1 2025: Johnson & Johnson announced their proposed acquisition of Intra-Cellular Therapies Johnson & Johnson announced in January 2025 its proposed acquisition of Intra-Cellular Therapies, signaling a move to bolster its neuroscience and mental health drug portfolio.
• Q2 2025: Renasant Corporation and The First Bancshares, Inc. merger Renasant Corporation completed its merger with The First Bancshares, Inc. on April 1, 2025, in an all-stock deal valued at $1.2 billion, expanding its banking and wealth management services across the Southeastern U.S.
• Q3 2025: Unilever PLC to Acquire Dr. Squatch, LLC Unilever announced the acquisition of U.S.-based men’s personal care brand Dr. Squatch for $1.5 billion, aiming to expand its presence in premium and high-growth categories.

Lancet Market Segmentation

Lancet Type Outlook

• Safety Lancet
• Push Button Safety Lancet
• Pressure Activated Safety Lancet
• Side Button Safety Lancet
• Personal Lancet

Lancet End User Outlook

• Hospitals & Clinics
• Diagnostic Centers and Pathology Laboratories
• Home Diagnostics
• Research and Academic Laboratories

Lancet Regional Outlook

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• Rest of the World
  • Middle East
  • Africa
  • Latin America

Attribute/Metric	Details
Market Size 2023	USD 1.95 billion
Market Size 2024	USD 2.13 billion
Market Size 2032	USD 3.88 billion
Compound Annual Growth Rate (CAGR)	6.91% (2024-2032)
Base Year	2022
Market Forecast Period	2024-2032
Historical Data	2018 - 2021
Market Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	Product Type, Operating Platforms, and Region
Geographies Covered	North America, Europe, Asia Pacific, and Rest of the World
Countries Covered	The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled	HTL-STREFA S.A. (Poland), Terumo Corporation (Japan), Becton Dickinson and Company (US), F.Hoffmann-La Roche Ltd (Switzerland), Improve Medical Instruments Co. Ltd. (US), Bayer AG (Germany), Sarstedt AG & Co. (Germany), Abbott Laboratories (US), Greiner Bio-One International GmbH (US), and others
Key Market Opportunities	·         Emergence of contagious and non-contagious diseases
Key Market Dynamics	·         Rising prevalence of diabetic patients ·         Increasing aged population ·         Increasing diabetes in children ·         Advanced technology